Clinical value of lncRNA CCAT1 in serum extracellular vesicles as a potential biomarker for gastric cancer.

Long non-coding RNAs (lncRNAs) in extracellular vesicles (EVs) are considered to be novel non-invasive biomarkers for gastric cancer (GC). lncRNA colon cancer-associated transcript 1 (CCAT1) is aberrantly expressed in certain types of cancer. However, the role of EV lncRNA CCAT1 in patients with GC remains unclear. The current study aimed to assess the expression levels of lncRNA CCAT1 in the serum EVs of patients with GC and evaluate its potential clinical value. EVs were isolated from serum using a commercial kit and ultracentrifugation, and were identified by transmission electron microscopy, nanoparticle tracking analysis and western blotting. Serum EV lncRNA CCAT1 levels in patients with GC, chronic gastritis or atypical hyperplasia and healthy control subjects were detected by reverse transcription-quantitative PCR. Additionally, lncRNA CCAT1 was detected in GC and adjacent non-cancerous tissue samples. Serum EVs were successfully isolated and identified in all patients. The results revealed that serum EV lncRNA CCAT1 levels in patients with GC were significantly higher compared with those in healthy controls, patients with chronic gastritis or atypical hyperplasia (all P<0.05). Additionally, EV lncRNA CCAT1 expression levels were significantly different among various groups based on the depth of invasion, distant metastasis and the Tumor-Node-Metastasis stage. The area under the curve (AUC) value of EV lncRNA CCAT1 was 0.890 [95% confidence interval (CI), 0.826-0.937] with 79.6% sensitivity and 92.6% specificity. The combination of EV lncRNA CCAT1 and carcinoembryonic antibody produced an AUC value of 0.910 (95% CI, 0.849-0.951) with the sensitivity and specificity of 80.5 and 92.6%, respectively. In addition, lncRNA CCAT1 was determined to be stable in serum EVs. The expression levels of lncRNA CCAT1 in GC tissue were positively correlated with those in serum EVs, and high levels of lncRNA CCAT1 were associated with a low disease-free survival rate in patients with GC. The results of the present study demonstrated that serum EV lncRNA CCAT1 levels were upregulated in patients with GC compared with those healthy subjects and patients with other illnesses, and may therefore be used as a novel biomarker for this type of cancer. Copyright: © Xiao et al.

Introduction

Gastric cancer (GC) is the third leading cause of cancer-associated deaths worldwide (1). The 5-year survival rate of patients with advanced GC is only 5–20%, with a median overall survival of 10 months worldwide (2,3). Therefore, early detection of GC is crucial for improving patient survival rates (4). Currently, endoscopy and pathological examination are the diagnostic gold standard; however, these procedures are invasive and costly. The detection of biomarkers in peripheral blood is a useful method for GC screening. The traditional tumor markers used for GC detection include carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and carbohydrate antigen 72-4 (CA72-4) (5). However, previous studies by our group (5) and Wang et al (6) have demonstrated that the sensitivity and specificity of the three traditional markers are insufficient for the diagnosis of GC, which limits their clinical utility. Thus, the identification of a diagnostic marker with high sensitivity and specificity for patients with GC is urgently required.

In the past decade, there has been notable progress in the field of study of extracellular vesicles (EVs), which have attracted increasing attention due to their widespread prevalence in various body fluids (7,8), ease of access (9,10) and association with various diseases (11). EVs are a heterogeneous population of cell-derived vesicles secreted by various cell types to mediate their intracellular communication (12). Following uptake by recipient cells, EVs serve a certain role in cancer progression; for example, Abd Elmageed et al (13) have reported that microRNA (miRNA or miR)-125b, miR-130 and miR-155, as well as HRas and Kras mRNAs in EVs from prostate cancer cells participate in neoplastic reprogramming and tumor formation of adipose stem cells. This hypothesis also has been supported by Zhang et al (14), who demonstrated that EVs derived from GC cells induce neutrophils to polarize to N2 tumor-associated neutrophils, thus promoting GC cell migration. EV membranes are enriched in various protein markers including CD9, CD63 and tumor susceptibility gene 101 (TSG101) (5). By means of EVs, various molecules such as lipids, proteins and nucleic acids [(DNA, mRNA and long non-coding RNA (lncRNA)] can be transferred from donor to recipient cells (15), suggesting that this mechanism may be involved in GC progression. In addition, circulating EVs are present in liquid biopsies and may be used as diagnostic markers of GC (16,17); therefore, EVs may have potential diagnostic value in GC.

lncRNAs have been reported to serve crucial roles in cancer development and progression (18). lncRNAs have a number of functions in various biological processes, including the cis or trans transcriptional and post-transcriptional regulation of RNA (19). An increasing number of lncRNAs have been demonstrated to participate in GC progression. For example, knockdown of lncRNA AF147447 promotes GC cell proliferation and invasion by directly binding to miR-34c (20). Gastric cancer metastasis-associated lncRNA (GMAN) promotes the expression of EphrinA1 through the GMAN-antisense pathway, promoting GC metastasis (21). In addition, circulating EVs loaded with specific bioactive molecules reflect the status of GC progression and metastasis (4). The EV-mediated transfer of lncRNA HOX transcript antisense RNA (HOTAIR) promotes cisplatin resistance in liver cancer cells by regulating the high mobility group AT-hook (HMGA)1/miR-218 axis (22). lncRNAs in EVs are stably present in circulation and are regarded as useful markers that are reflective of disease status. Previous studies have reported that certain EV lncRNAs are highly expressed in the serum of patients with GC, including LINC00152, lncRNA HOTTIP and lncUEGC1 (23–25). The results of the aforementioned studies suggest that EV lncRNAs may be used as auxiliary biomarkers of GC. However, certain limitations, such as their lack of clinical efficiency and clinical effect require further consideration.

lncRNA colon cancer-associated transcript-1 (CCAT1) is an oncogenic lncRNA located on chromosome 8q24, close to the gene encoding c-Myc (26). lncRNA CCAT1 has been reported to be elevated in certain types of cancer, such as GC (27), colorectal cancer (CRC) (28) and hepatocellular carcinoma (29). Additionally, lncRNA CCAT1 serves a crucial role in various biological processes, such as cell proliferation and invasion (30). Aberrant expression of lncRNA CCAT1 affects tumorigenesis, tumor size, lymph node metastasis, Tumor-Node-Metastasis (TNM) stage, tumor differentiation and invasion (31,32). A previous study by Shen et al (33) has revealed that lncRNA CCAT1 serves a role in cervical cancer by promoting cell proliferation and invasion via the regulation of the miR-181a-5p/MMP14 axis. You et al (34) have also demonstrated that CCAT1 promotes the proliferation of prostate cancer cells by facilitating androgen receptor (AR) expression as a scaffold for DEAD-box helicase 5 (P68) and the AR transcriptional complex, and by acting as a sponge of miR-28-5p to prevent its anticancer effects. lncRNA CCAT1 can be used as a diagnostic marker; Abedini et al (35) have demonstrated that the levels of plasma lncRNA CCAT1 in patients with CRC are higher compared with those in healthy control subjects. In GC, lncRNA CCAT1 contributes to tumor growth and invasion by targeting miR-219-1 (36). This suggests that lncRNACCAT1 is involved in the progression of GC and may serve as a potential biomarker.

lncRNAs can exist stably in the peripheral circulation and are protected by EVs. As markers, EVs have a good diagnostic value in GC; for example, a previous study has demonstrated that lncRNA zinc finger NFX1-type containing 1 antisense RNA 1 levels are elevated in the serum exosomes of patients with GC compared with those in healthy controls (37). Furthermore, Li et al (23) have determined that plasma LINC00152 levels are significantly higher in patients with GC compared with those in healthy controls. lncRNA CCAT1 has also been identified in the plasma and serum EVs of patients with CRC (38,39). However, to the best of our knowledge, there no studies are currently available on EV lncRNA CCAT1 in patients with GC. Therefore, the current study aimed to identify the levels of lncRNA CCAT1 in the serum EVs of patients with GC and evaluate its expression and diagnostic value. In addition, the correlation of lncRNA CCAT1 with various clinicopathological variables was assessed. The present study further aimed to identify a reliable biomarker in the diagnosis of GC.

Materials and methods

Patients and control subjects

Serum samples of 27 healthy control subjects, 26 patients with chronic gastritis, 30 patients with atypical hyperplasia and 113 patients with GC were collected at the Qilu Hospital of Shandong University between January and December 2017. Peripheral blood samples from the GC group were collected before surgery. The age ranges in the subject groups were as follows: Healthy controls, 29–62 (male subjects, n=8) and 30–66 (female subjects, n=19); chronic gastritis, 32–69 (male patients, n=14) and 33–65 (female patients, n=12); atypical hyperplasia 33–73 (male patients, n=21) and 41–73 (female patients, n=9); GC, 25–82 (male patients, n=84) and 23–74 (female patients, n=29) years. In addition, 16 paired GC and adjacent non-cancerous tissues were collected during surgical resection and stored at −80°C immediately. The distance between the tumor margin and the adjacent non-tumor tissue ≥5 cm. The demographic and clinicopathological characteristics of all participants were recorded. GC was diagnosed by two pathologists and staged according to the Union for International Cancer Control/American Joint Committee on Cancer TNM staging system (8th edition) (40). No patients had received any adjuvant therapy such as radiotherapy or chemotherapy prior to sample collection. The inclusion criteria for the healthy control subjects were routine blood test, biochemical index, tumor marker and imaging test results determined to be within the reference range during physical examination. Outliers were defined through Tukey's box-plot method (41), and 4, 5, 3 and 6 suspected outliers were removed from healthy controls, patients with chronic gastritis, atypical hyperplasia and GC, respectively. In addition, four pairs of GC and adjacent non-cancerous tissues were removed as outliers. The present study was approved by the Medical Ethics Committee of Qilu Hospital of Shandong University (approval no. KYLL-2015-097). All participants provided signed informed consent.

Isolation of EVs from serum

Serum was collected from 5 ml venous blood by centrifuging at 3,000 × g for 10 min at room temperature. The samples were filtered through a 0.22-µm filter (Millipore Sigma) to eliminate cell fragments and organelles. Two methods were used to isolate EVs. For the commercial kit method, the serum was centrifuged at 50,000 × g for 60 min to remove large microbubbles, and the subsequent procedures were performed according to the manufacturer's instructions of the exoEasyMaxi kit (cat. no. 76064; Qiagen GmbH). Briefly, 1 ml serum was mixed with 1 ml XBP buffer and added to the exoEasy spin column (in a 50-ml collection tube to bind EVs). Following centrifugation at 500 × g for 60 sec, 10 ml XWP buffer was added and centrifuged at 5,000 × g for 5 min, and 400 µl XE buffer was used to elute EVs at 500 × g for 5 min. For ultracentrifugation, 1 ml serum was diluted 1:7 in PBS and centrifuged at 120,000 × g for 2 h. A lamellar precipitate was observed at the bottom of the tube, the main component of which was EVs. The supernatant was discarded and the EVs were resuspended with 100 µl PBS. All centrifugation steps were performed at 4°C unless stated otherwise.

Transmission electron microscopy (TEM)

A total of 10 µl EV suspension was added to a 200-mesh carbon film copper net. The carbon film was allowed to absorb EVs for 20 min in a dry environment. The copper net was sequentially placed in 50 µl 11% glutaraldehyde, 100 µl ddH2O, 50 µl uranyl acetate and 50 µl methylcellulose-uranyl acetate droplets. The excess liquid was gently removed using filter paper, leaving a thin methylcellulose film, which was dried for 5–10 min at room temperature. The samples were observed in 5–10 fields per sample under a Hitachi HT7800 transmission electron microscope (Hitachi High-Tech Corporation) at 80 kV under ×40,000 magnification.

Measurement of size distribution

The size distribution of EVs was observed on a ZetaView analyzer (Particle Metrix GmbH) according to the manufacturer's instructions. Nanoparticle Tracking Analysis (NTA) was used to capture the Brownian motion of each particle in the video. Based on the different diffusion movements of large and small particles in the surrounding liquid, the hydrodynamic diameters of particles were determined. In addition, the charge state of particle surface (zeta potential) was measured by determining the movement of particles in an applied electric field.

EV protein quantification and western blot analysis

EVs were suspended in RIPA lysis buffer (cat. no. P0013B; Beyotime Institute of Biotechnology) on ice to dissolve the protein. Total protein concentration was determined by BCA protein detection kit (cat. no. P0012; Beyotime Institute of Biotechnology). The extracted protein was diluted with loading buffer 4:1 and incubated at 100°C for 5 min. A total of ~20 µg EV protein per lane was separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis, transferred to PVDF membranes, blocked in 5% non-fat milk for 1 h and incubated overnight at 4°C with primary mouse anti-CD63 (cat. no. ab59479; 1:1,000; Abcam), rabbit anti-TSG101 (cat. no. ab125011; 1:1,000; Abcam), rabbit anti-CD9 (cat. no. 13403s; 1:1,000; Cell Signaling Technology, Inc.), rabbit anti-GAPDH (cat. no. AB-P-R 001; 1:1,000; Hangzhou Good Here Biotechnology Co., Ltd.) and rabbit anti-calnexin (cat. no. 2679s; 1:1,000; Cell Signaling Technology, Inc.) antibodies. The washing reagent TBST (cat. no. T1081; Beijing Solarbio Science & Technology Co., Ltd.) used to remove the primary antibodies The horseradish peroxidase-labeled goat anti mouse (cat. no. A0216; 1:2,000; Beyotime Institute of Biotechnology) or goat anti rabbit antibody (cat. no. A0208; 1:2,000; Beyotime Institute of Biotechnology) was used to imprint the target protein and incubated at room temperature for 1 h. The diluent for the secondary antibody (cat. no. WB100D) was purchased from New Cell & Molecular Biotech Co., Ltd. The protein signals were detected by an enhanced chemiluminescence detection system (Amersham Imager 680; Cytiva).

RNA extraction and reverse transcription-quantitative (RT-q)PCR

Serum and tissue RNAs were extracted using an exoRNeasy Serum/Plasma Midi kit (cat. no. 77044; Qiagen GmbH) and RNAprep pure FFPE kit [cat. no. DP439; TIANGEN Biotech (Beijing) Co., Ltd.] according to the manufacturer's instructions. An All-in-one™ First-Strand cDNA Synthesis kit (cat. no. QP006; GeneCopoeia, Inc.) was used to reverse-transcribe an equal amount of total RNA from each sample to cDNA according to the manufacturer's instructions. cDNA was diluted 1:5 with ddH2O, and qPCR was performed using a CFX96 qPCR instrument (Bio-Rad Laboratories, Inc.) with an All-in-one™ qPCR Mix (cat. no. QP001; GeneCopoeia, Inc.). The primers used were lncRNA CCAT1 forward, 5′-AGGGGCTCTCCTTTTGTTCG-3′ and reverse, 5′-GATTTCAGCAGCGAGGGTCT-3′ (88 bp); GAPDH (cat. no. B662104; 138 bp) was purchased from Sangon Biotech Co., Ltd. The thermocycling conditions were as follows: Initial denaturation at 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec, 62°C for 20 sec and 72°C for 10 sec. The amplification specificity was determined by melting curve analysis. Data were normalized to GAPDH, and relative expression levels were evaluated using the 2−ΔΔCq method (42). No template reaction and no RT reaction were used as negative controls.

Stability of serum EV lncRNA CCAT1 in harsh environments

EVs from patient serum were divided into three groups that were untreated (control), treated with RNase A or treated with RNase A plus 0.1% Triton X-100 for 45 min at 37°C, respectively. In order to evaluate the stability of lncRNA CCAT1 in serum EVs in harsh environments, serum samples were stored at room temperature or 4°C for 24 or 48 h. In addition, serum samples were frozen and thawed three times at −80°C, and fresh serum used as a control. Following these treatments, the expression levels of lncRNA CCAT1 were detected by RT-qPCR.

Fecal occult blood tests

The bleeding of digestive tract was measured by colloidal gold-based Fecal Occult Blood diagnostic kit (Shanghai Chemtron Biotech Co., Ltd.).

Online bioinformatics analysis

The expression levels of EV lncRNA CCAT1 were assessed in various diseases using the online database exoRBase (http://www.exorbase.org/), which is a repository of lncRNAs derived from RNA-seq data analyses of human blood exosomes (43). GEPIA (http://gepia.cancer-pku.cn/index.html) was used to obtain the Kaplan-Meier curve to analyze the association between the expression of CCAT1 and survival times (months) of patients, including overall survival (OS) and disease-free survival (DFS).

Statistical analysis

Data are presented as the median and interquartile ranges or the mean ± SD. SPSS version 25.0 (IBM Corp.) and MedCalc version 8.0 (MedCalc Software, Ltd.) were used for statistical analyses. The Kolmogorov-Smirnov test was used to determine the data distribution in each group. Serum EV lncRNA CCAT1 levels were evaluated by the Mann Whitney U or Kruskal Wallis test in different groups based on patient clinicopathological characteristics. Data on the stability of serum EV lncRNA CCAT1 were analyzed using one-way ANOVA followed by Tukey's post hoc test or two-way ANOVA followed by Bonferroni post hoc test. lncRNA CCAT1 levels in paired samples of GC tissues were analyzed with Wilcoxon's signed rank test. Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic value of biomarkers in GC, and area under the curve (AUC) was calculated. The cut-off value was calculated using the Jordan index (sensitivity + specificity-1). OS and DFS were analyzed by Kaplan-Meier estimates and examined by log-rank test. The correlations between EV lncRNA CCAT1 in the serum of patients with GC and CCAT1 in GC tissues were determined by Spearman's correlation analysis. P<0.05 was considered to indicate a statistically significant difference.

Results

Characterization of serum EVs

EVs were extracted using a commercial kit and ultracentrifugation. The results of TEM analysis demonstrated that EVs presented with a unique morphology with dish-like vesicles and a double-lipid layer (Fig. 1A). In addition, NTA revealed that the diameters of EVs extracted using a commercial kit and ultracentrifugation were 125.6±51.7 and 119.5±51.8 nm, respectively (Fig. 1B). The zeta potentials for the commercial kit and ultracentrifugation were-21.41±1.93 and −16.46±1.90 mV (P=0.061), respectively (data not shown). Surface marker proteins including CD9, CD63, TSG101, the negative control protein calnexin and GAPDH (used as a loading control) were identified in the two groups of EVs (Fig. 1C). The EVs obtained using the commercial kit were similar to those obtained by ultracentrifugation.

Figure 1.

Characterization of serum EVs. EVs were isolated and characterized from human serum using a commercial kit and ultracentrifugation. (A) Transmission electron microscopy micrographs. Magnification, ×40,000. (B) The size distribution of EVs was determined using a particle tracking analyzer. (C) Western blot analysis of EV markers CD9, CD63, TSG101 and calnexin. EVs, extracellular vesicles; TSG101, tumor susceptibility gene 101.

Serum EV lncRNA CCAT1 levels in patients with GC, chronic gastritis and atypical hyperplasia as well as healthy control subjects

The results of the bioinformatics analysis revealed that the levels of lncRNA CCAT1 were upregulated in hepatocellular carcinoma and pancreatic adenocarcinoma compared with those in healthy controls (Fig. S1). However, there no data were available for lncRNA CCAT1 expression in patients with GC. The data obtained in the current study revealed that serum EV lncRNA CCAT1 levels in patients with GC [4.170 (2.250–11.740)] were significantly higher compared with those in the healthy controls [0.910 (0.400–1.630)], patients with chronic gastritis [0.710 (0.406–5.453)] and atypical hyperplasia [1.812 (0.434–8.321)] (all P<0.05). Furthermore, lncRNA CCAT1 expression levels were higher in patients with atypical hyperplasia compared with those in healthy controls (P<0.05; Fig. 2). No differences were observed in the CCAT1 expression levels between patients with chronic gastritis and healthy controls or patients with atypical hyperplasia.

Figure 2.

Serum levels of EV long non-coding RNA CCAT1 in patients with gastric cancer, atypical hyperplasia and chronic gastritis, as well as healthy control subjects. EV, extracellular vesicle; CCAT1, colon cancer-associated transcript 1.

Correlation between serum EV lncRNA CCAT1 levels and the clinicopathological features of patients with GC

The current study evaluated the clinical value of CEA and EV lncRNA CCAT1 in patients with GC. The results demonstrated that high expression levels of EV lncRNA CCAT1 were significantly associated with the depth of invasion (P=0.040), distant metastasis (P<0.001) and TNM stage (P<0.001). However, there was no significant association between EV lncRNA CCAT1 levels and patient sex, age, cancer location, Bormann classification, tumor diameter, differentiation, lymphatic metastasis, hypertension or fecal occult blood (Table I). CEA levels were associated with tumor diameter, depth of invasion and TNM stage (5).

Table I.

Extracellular vesicle long non-coding RNA CCAT1 expression levels and patient clinicopathological characteristics.

Variable	n	CCAT1, median (interquartile range)	U value	P-value
Sex			1,171.500	0.760
Male	84	4.200 (2.285, 10.910)
Female	29	4.070 (2.200, 13.505)
Age, years			1,315.500	0.111
≤61	59	3.560 (2.200, 9.080)
>61	54	4.465 (2.493, 16.155)
Cancer location			5.625[a]	0.131
Antrum	44	3.405 (2.026, 7.400)
Angulus	21	3.690 (1.300, 10.190)
Cardia	27	6.020 (2.610, 21.690)
Body	21	4.280 (2.740, 16.180)
Tumor diameter			1,352.000	0.161
≤3 cm	56	3.625 (2.255, 6.603)
>3 cm	57	4.370 (2.235, 15.185)
Differentiation			3.821[a]	0.148
Well differentiated	12	3.565 (1.678, 4.583)
Moderately differentiated	25	2.700 (1.715, 11.090)
Poorly differentiated	76	4.715 (2.345, 14.553)
Bormann type			0.180[a]	0.981
I	18	4.085 (2.330, 7.472)
II	55	4.230 (2.200, 14.840)
III	25	4.340 (2.420, 12.780)
IV	15	3.580 (2.110, 12.670)
Invasion depth			8.307[a]	0.040
T1	26	3.525 (2.350, 5.618)
T2	21	3.040 (1.210, 4.715)
T3	22	6.650 (2.790, 17.353)
T4	44	4.705 (2.268, 17.405)
Lymphatic metastasis			1,252.500	0.074
No	48	3.445 (2.028, 6.525)
Yes	65	4.470 (2.400, 15.185)
Distant metastasis			289	<0.001
No	95	3.560 (2.110, 6.690)
Yes	18	20.135 (8.815, 25.645)
Tumor-Node-Metastasis stage			21.851[a]	<0.001
I	37	3.140 (1.685, 4.995)
II	28	3.935 (2.038, 11.840)
III	30	3.905 (2.178, 9.135)
IV	18	20.135 (8.815, 25.645)
Hypertension			1,018.500	0.190
No	84	3.775 (2.208, 9.228)
Yes	29	6.020 (2.360, 18.150)
Fecal occult blood			1,017.500	0.076
No	81	4.340 (2.455, 13.260)
Yes	32	3.090 (1.978, 7.328)

H-value. CCAT1, colon cancer-associated transcript 1.

Diagnostic value of serum EV lncRNA CCAT1 levels in GC

Serum EV lncRNA CCAT1 levels were significantly higher in patients with stage III+IV GC [7.250 (2.525–19.630)] compared with those in patients with stage I+II GC [3.490 (1.955–6.185)] (P=0.012; Fig. 3A). This suggested that EV lncRNA CCAT1 may be a reliable biomarker of GC. The predictive value of EV lncRNA CCAT1 was subsequently determined. The AUC of EV lncRNA CCAT1 was [0.890; 95% confidence interval (CI), 0.826–0.937)], which indicated a good capability to diagnose patients with GC. The cut-off, sensitivity and specificity values of EV lncRNA CCAT1 were 1.990, 79.6 and 92.6%, respectively (Table II). lncRNA CCAT1 and CEA were combined to assess their ability to diagnose GC. ROC analysis demonstrated that the AUC of the combined markers was 0.910 (95% CI, 0.849–0.951; Fig. 3B). The sensitivity and specificity of combined lncRNA CCAT1 and CEA were 80.5 and 92.6%, respectively.

Figure 3.

Diagnostic value of serum EV lncRNA CCAT1 in GC. (A) Expression of lncRNA CCAT1 in patients with GC and different Tumor-Node-Metastasis stages. lncRNA CCAT1 was normalized to GAPDH. (B) ROC curve analyzing the diagnostic value of EV lncRNA CCAT1 and CEA. EV, extracellular vesicle; lncRNA, long non-coding RNA; CCAT1, colon cancer-associated transcript 1.

Table II.

Predictive value of CEA and long non-coding RNA CCAT1 in extracellular vesicles in gastric cancer.

Marker	Cut-off	Sens (95% CI)	Spec (95% CI)	AUC (95% CI)
CCAT1	1.990	79.600 (71.000–86.600)	92.600 (75.700–98.900)	0.890 (0.826–0.937)
CCAT1 + CEA		80.500 (72.000–87.400)	92.600 (75.700–98.900)	0.910 (0.849–0.951)

CCAT1, colon cancer-associated transcript 1; CEA, carcinoembryonic antibody; Sens, sensitivity; Spec, Specificity; CI, confidence interval; AUC, area under the curve.

To determine the stability of serum EV lncRNA CCAT1, EVs from patient serum were divided into three groups. The results revealed that there was no significant differences between the RNase A treatment and control groups; however, when TritonX-100 penetrated the EVs, the expression levels of EV lncRNA CCAT1 decreased significantly (Fig. S2). These results confirmed that lncRNA CCAT1 was present in serum EVs. To verify the stability of lncRNA CCAT1 in serum EVs in harsh environments, serum samples were stored at room temperature or 4°C for 24 or 48 h (Fig. S3A). With fresh serum as a control, serum samples were frozen and thawed three times at −80°C (Fig. S3B). The results demonstrated that the aforementioned treatments had no significant effects on the expression of lncRNA CCAT1 in EVs, which confirmed that the expression levels of serum EV lncRNA CCAT1 were stable.

Expression of lncRNA CCAT1 in GC tissues

A previous study has suggested that circulating EV lncRNA may be secreted from GC tissues (44). Therefore, the current study assessed the source of serum EV lncRNA CCAT1. The results demonstrated that lncRNA CCAT1 levels in GC tissues were significantly higher compared with those in the adjacent tissues (P<0.001; Fig. S4A). The correlation analysis between lncRNA CCAT1 in GC tissues and serum EVs revealed a positive correlation (r=0.685; P=0.003; Fig. S4B). These results suggested that serum EV lncRNA CCAT1 may be secreted from GC cells.

Prognostic value of lncRNA CCAT1 expression in GC

To evaluate the value of lncRNA CCAT1 in GC prognosis, GEPIA (http://gepia.cancer-pku.cn/index.html) was used. As presented in Fig. 4A, low expression levels of lncRNA CCAT1 were significantly associated with a favorable DFS outcome compared with high expression levels of lncRNA CCAT1 in patients with GC [hazard ratio (HR)=1.7; log-rank P=0.038]. However, it exhibited no significance in predicting OS (HR=1.3; log-rank P=0.310; Fig. 4B). These results suggested that lncRNA CCAT1 may be a useful biomarker for predicting the DFS of patients with GC.

Figure 4.

Prognostic value of CCAT1 in patients with gastric cancer. (A) Long non-coding RNA CCAT1 expression levels were significantly associated with disease-free survival. (B) No significant association was observed between CCAT1 expression levels and overall survival. CCAT1, colon cancer-associated transcript 1.

Discussion

Recent studies have demonstrated that EV lncRNAs are reliable biomarkers for various types of cancer including breast cancer, CRC and hepatocellular carcinoma (45–47). Previous studies have reported that lncRNA LINC00152, HOTTIP and lncUEGC1 in EVs may be suitable biomarkers for GC, and their AUC values were 0.657, 0.827 and 0.876, respectively (23–25). Furthermore, the sensitivity and specificity of the aforementioned three lncRNAs were 48.1 and 85.2, 69.8 and 85.0, and 88.24 and 83.33%, respectively (23–25). Notably, the AUC, sensitivity and specificity of lncRNA CCAT1 in the current study were 0.890, 79.6 and 92.6%, respectively, which were higher compared with those of the aforementioned three lncRNAs, suggesting that it may be a reliable potential biomarker. Furthermore, the levels of EV lncRNA CCAT1 were associated with depth of invasion, distal metastasis and TNM stage, but not associated with other clinicopathological features, such as patient age and sex in the present study. Serum EV lncRNA CCAT1 was also positively correlated with its expression in GC tissues and associated with the prognosis of patients with GC. These results suggested that EV lncRNA CCAT1 may be a reliable tumor marker for GC.

EVs are involved in the key steps of cancer progression and have numerous potential applications in diagnosis and treatment. A previous study has demonstrated that tumor cells secrete EVs into various body fluids, including the blood and urine (48). In the current study, EVs were successfully isolated from the serum, which was consistent with previous studies (49,50). EVs contain a wide range of DNA, mRNA, proteins, miRNA, lncRNA, circular RNA and metabolites (51). EVs are involved in the development of GC through intercellular communication (16). Therefore, EVs are regarded as suitable non-invasive biomarkers for GC. Multiple methods to obtain EVs are available, including density-gradient centrifugation, sucrose cushion centrifugation, gel-permeation chromatography, affinity capture, microfluidic devices, synthetic polymer-based precipitation and membrane filtration (52). The current study compared the efficiency of EV extraction by ultracentrifugation and a commercial kit. The results demonstrated that EVs were successfully obtained by both methods, and that their characteristics were similar, as determined by TEM, surface marker proteins, size distribution and zeta potential. Compared with the that obtained using the commercial kit, the yield of EVs extracted by ultracentrifugation was higher; however, the purity was lower. In addition, ultracentrifugation is time-consuming, thus it is recommended that commercial kits are used to obtain EVs in future studies.

lncRNA CCAT1 silencing inhibits PANC-1 and Aspc-1 PC cell proliferation and migration, and rescues cyclin D1 expression (32). Another study has revealed that lncRNA CCAT1 promotes the proliferation and migration of HCC cells in vitro by depressing the expression levels of let-7, targeting high mobility group AT-hook 2 and c-Myc (31). The development of GC is a complex process, starting with chronic gastritis, which subsequently progresses to atypical hyperplasia and finally GC. Alterations in the resulting EV lncRNAs of these processes that are secreted into the periphery may therefore serve as suitable biomarkers.

The present study assessed the potential clinical value of EV lncRNA CCAT1. The results revealed that EV lncRNA CCAT1 levels in patients with GC were significantly higher compared with those in healthy control subjects, as well as in patients with chronic gastritis and atypical hyperplasia. These results suggested that EV lncRNA CCAT1 may be involved in GC progression. It is hypothesized that during GC progression, abnormal cells release EVs containing lncRNA CCAT1, which enter the periphery; once EVs bind to target cells, their contents can be transferred to the cytoplasm through a variety of pathways, thus altering the physiological state of the receptor cells (53). Kalluri and LeBleu (54) have demonstrated that EVs downregulate the levels of major histocompatibility complex-II transcription factor regulatory factor X associated protein in dendritic cells, potentially promoting immune evasion by cancer cells. In addition, EVs activate macrophages and increase the levels of proinflammatory cytokines, which in turn promote the proliferation and migration of tumor cells, leading to the reconstruction of the tumor microenvironment (55). In addition, atypical hyperplasia is a key step for the progression from a healthy state to GC (56). The results of the present study revealed that the expression levels of lncRNA CCAT1 in atypical hyperplasia were higher compared with those in healthy control subjects, which further confirmed its role in GC progression. A previous study has demonstrated that lncRNAs exist stably in the blood, possibly to protect EVs from degradation (44). The results of the current study demonstrated that serum EV lncRNA CCAT1 was expressed at stable levels, and that there were no significant changes in the expression levels of lncRNA CCAT1 at different times, temperatures and conditions of repeated freezing and thawing, suggesting that serum EV lncRNA CCAT1 may be suitable as a biomarker of GC. The results of the present study also demonstrated that lncRNA CCAT1 was associated with various clinical parameters that may be involved in the invasion and metastasis of GC. The mechanism by which lncRNA CCAT1 exerts its functions may be activated by c-Myc or the upregulation of Bmi-1 to promotes the proliferation, migration and invasion of GC cells (36,57,58).

In the present study, EV lncRNA CCAT1 levels were markedly higher in patients with stage III+IV GC compared with those with stage I+II GC. These results suggested that with GC development, the expression levels of lncRNA CCAT1 in the serum were increased; thus, lncRNA CCAT1 may be associated with GC progression. ROC curve analysis revealed that EV lncRNA CCAT1 had a markedly higher diagnostic value compared with that of CEA. An increasing body of evidence has demonstrated that a combination of multiple tumor markers may improve the accuracy of diagnosis. For examples, Zhao et al (59) have reported that the combination of lncRNA CCAT1 and lncRNA HOX transcript antisense RNA provides more effective screening for CRC compared with HOTAIR or CCAT1 alone. In addition, Li et al (60) have demonstrated that the diagnostic value of EV lnc-GNAQ-6:1 was higher compared with that of traditional tumor markers CEA, CA 19–9 and CA72-4, and that the combination of these markers may provide an effective screening method for GC. The current study combined lncRNA CCAT1 and CEA to evaluate the diagnostic value of this combination in GC, and reached similar conclusions; the markers were more effective in combination compared with the results obtained with each marker alone.

Previous studies have suggested that serum/plasma EV lncRNA is secreted from tumor tissues. Tong et al (61) have reported that the expression of lncRNA POU class 3 homeobox 3 is consistent in the tissues and serum of patients with esophageal squamous cell carcinoma. The results of the present study demonstrated that the expression levels of lncRNA CCAT1 in GC tissues were higher compared with those in adjacent non-cancerous tissues and were positively correlated with those in the serum. It was hypothesized that lncRNA CCAT1 may be secreted by cancer cells during GC progression. The online database exoRBase analysis revealed that EV lncRNA CCAT1 levels were upregulated in hepatocellular carcinoma and pancreatic adenocarcinoma compared those in healthy subjects. However, there was a lack of data from patients with GC. Therefore, the current study may provide novel information for the GC diagnosis.

A previous study has demonstrated that lncRNAs are associated with the poor prognosis of several types of cancer including lung adenocarcinoma, hepatocellular carcinoma and melanoma (62). In the present study, patients with high expression levels of lncRNA CCAT1 presented with a poor prognosis. Similarly, a study by Ozawa et al (63) has determined that high lncRNA CCAT1 expression levels are significantly associated with low remission-free survival and OS rates in patients with CRC. Taken together, these results suggested lncRNA CCAT1 may be used as a biomarker to diagnose and determine the prognosis of patients with GC. However, there were limitations to the present study, including its retrospective nature and a relatively small sample size. Further studies with a larger sample size that aim to determine the underlying mechanism of EV lncRNA CCAT1 in GC progression are therefore required.

In conclusion, the results of the current study demonstrated that the levels of serum EV lncRNA CCAT1 were significantly upregulated in patients with GC compared with those in healthy subjects and patients with other illnesses, demonstrating the diagnostic value of this lncRNA. In addition, the levels of EV lncRNA CCAT1 were associated with the depth of invasion and metastasis. lncRNA CCAT1 existed stably in serum EVs and may be derived from GC cells. These results provide a foundation for further analysis of the clinical value of EV lncRNA CCAT1 in the diagnosis and prognosis of patients with GC.